Quantification of ex vivo generated dendritic cells (DC) and leukemia-derived DC contributes to estimate the quality of DC, to detect optimal DC-generating methods or to optimize DC-mediated T-cell-activation-procedures ex vivo or in vivo [16]

Leukemia

Volumn 21, Issue 6, 2007, Pages 1338-1341

  Schmetzer, H M ^a   Kremser, A ^a   Loibl, J ^a   Kroell, T ^a   Kolb, H J ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

B7 ANTIGEN; CD137 LIGAND; CD1B ANTIGEN; CD1C ANTIGEN; CD40 ANTIGEN; CD83 ANTIGEN; CD86 ANTIGEN; DENDRITIC CELL VACCINE; T6 ANTIGEN;

ACUTE GRANULOCYTIC LEUKEMIA; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; CANCER IMMUNOTHERAPY; CELL DIFFERENTIATION; CELLULAR IMMUNITY; CLINICAL TRIAL; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; EX VIVO STUDY; HUMAN; IN VIVO STUDY; LETTER; LEUKEMIA CELL; LEUKEMIA REMISSION; NATURAL KILLER CELL; PRIORITY JOURNAL; PROCESS OPTIMIZATION; QUANTITATIVE ANALYSIS; T LYMPHOCYTE ACTIVATION; TUMOR IMMUNITY;

EID: 34249752808     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/sj.leu.2404639     Document Type: Letter

References (13)

1. Schmid C, Schleuning M, Schwerdtfeger R, Hertenstein B, Mischak-Weisinger E, Bunjes D et al. Long-term survival in refractory acute myeloid leukaemia after sequential treatment with chemotherapy and reduced-intensity conditioning for allogeneic stem cell transplantation. Blood 2006; 108: 1092-1099.
2. Choudhury A, Liang JC, Thomas EK, Flores-Romo L, Xie QS, Agusala K et al. Dendritic cells derived in vitro from acute myelogenous leukaemia cells stimulate autologous, anti-leukemic T-cell responses. Blood 1999; 93: 780-786.
3. Kufner S, Kroell T, Pelka-Fleischer R, Schmid C, Zitzelsberger H, Salih H et al. Serum-free generation and quantification of functionally active leukaemia-derived dendritic cells is possible from malignant blasts in acute myeloid leukaemia (AML) and myelodysplastic syndromes (MDS). Cancer Immunol Immunther 2005; 54: 953-970.
4. Mutis T, Verdijk R, Schrama E, Esendam B, Brand A, Goulmy E. Feasibility of immunotherapy of relapsed leukaemia with ex-vivo generated cytotoxic T lymphocytes specific for hematopoietic system -restricted minor histocompatibility antigens. Blood 1999; 93: 2336-2341.
5. Gao L, Bellantuono I, Elsasser A, Marley SB, Gordon MY, Goldman JM et al. Selective elimination of leukemic CD34(+) progenitor cells by cytotoxic T lymphocytes specific for WT1. Blood 2000; 95: 2198-2203.
6. Roddie PH, Horton Y, Turner M. Primary acute myeloid leukaemia blasts resistant to cytokine-induced differentiation to dendritic like leukaemia cells can be forced to differentiate by the addition of bryostatin-1. Leukemia 2002; 16: 84-93.
7. Roddie H, Klammer M, Thomas C, Thomson R, Atkinson A, Sproul A et al. Phase I/II study of vaccination with dendritic-like leukaemia cells for the immunotherapy of acute myeloid leukaemia. Brit J Haemotol 2006; 133: 152-157.
8. Li L, Giannopoulos K, Reinhardt P, Tabarkiewicz J, Schmitt A, Greiner J et al. Immunotherapy for patients with acute myeloid leukemia using autologous dendritic cells generated from leukemic blasts. Int J Oncol 2006, 855-861.
9. Womer K, Peng R, Patton P, Murawski MR, Bucci M, Kaleem A et al. The effect of renal transplantation on peripheral blood dendritic cells. Clin Transplant 2005; 19: 659-667.
10. Graf M, Reif S, Hecht K, Pelka-Fleischer R, Kroel T, Pfister K et al. High expression of costimulatory molecules correlates with low relapseíree-survival-probability in Acute Myeloid Leukemia (AML). Ann Hematol 2005; 84: 287-297.
11. Pietschmann P, Stoeckl J, Draxler S, Majdic O, Knapp W. Functional and phenotypic characteristics of dendritic cells genereated in human plasma supplemented medium. Scand J Immunol 2000; 51: 377-383.
12. Loibl J, Kremser A, Schmid C, Zitzelsberger H, Kroell T, Scholl N et al. Surface marker expression profiles have to be evaluated before and after the generation of dendritic cells (DC) from blasts in acute myeloid leukaemia (AML) and myelodysplastic syndromes (MDS) to characterize and quantify DC in experimental settings. 2007, submitted for publication.
13. Houtenbos I, Westers G, Ossenkoppele GJ, van de Loosdrecht AA. Leukemia-derived dendritic cells: Towards clinical vaccination protocols in acute myeloid leukaemia. Haematologica 2006; 91: 348-355.